How to participate in a multiple sclerosis clinical trial

J. A. Frank, H. F. McFarland

Research output: Contribution to journalArticle

Abstract

MR imaging has made significant and important contributions in the understanding of the natural history of multiple sclerosis. The role of MR imaging and its importance in clinical trials will continue to increase over the next years, not only as a secondary outcome measure in pivotal trials but also as a method of monitoring therapeutic responses in early phase trials. As we move forward in our understanding of the underlying pathophysiology and immunology of MS, correlation with MR imaging measures of disease activity will be essential to translate from the research bench to the patient's bedside, and to use MR imaging more effectively in treatment trials. Neuroimaging groups can provide the required expertise and work together with both clinicians and the pharmaceutical companies in designing MS treatment trials that incorporate clinical and MR imaging outcome measures to determine the effectiveness and long-term benefits to patients of new treatments for MS.

Original languageEnglish (US)
Pages (from-to)817-830
Number of pages14
JournalNeuroimaging Clinics of North America
Volume10
Issue number4
StatePublished - 2000
Externally publishedYes

Fingerprint

Multiple Sclerosis
Clinical Trials
Outcome Assessment (Health Care)
Therapeutics
Allergy and Immunology
Neuroimaging
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Clinical Neurology
  • Radiological and Ultrasound Technology

Cite this

How to participate in a multiple sclerosis clinical trial. / Frank, J. A.; McFarland, H. F.

In: Neuroimaging Clinics of North America, Vol. 10, No. 4, 2000, p. 817-830.

Research output: Contribution to journalArticle

Frank, JA & McFarland, HF 2000, 'How to participate in a multiple sclerosis clinical trial', Neuroimaging Clinics of North America, vol. 10, no. 4, pp. 817-830.
Frank, J. A. ; McFarland, H. F. / How to participate in a multiple sclerosis clinical trial. In: Neuroimaging Clinics of North America. 2000 ; Vol. 10, No. 4. pp. 817-830.
@article{8606326f27df4351b1d54dcfe27fa439,
title = "How to participate in a multiple sclerosis clinical trial",
abstract = "MR imaging has made significant and important contributions in the understanding of the natural history of multiple sclerosis. The role of MR imaging and its importance in clinical trials will continue to increase over the next years, not only as a secondary outcome measure in pivotal trials but also as a method of monitoring therapeutic responses in early phase trials. As we move forward in our understanding of the underlying pathophysiology and immunology of MS, correlation with MR imaging measures of disease activity will be essential to translate from the research bench to the patient's bedside, and to use MR imaging more effectively in treatment trials. Neuroimaging groups can provide the required expertise and work together with both clinicians and the pharmaceutical companies in designing MS treatment trials that incorporate clinical and MR imaging outcome measures to determine the effectiveness and long-term benefits to patients of new treatments for MS.",
author = "Frank, {J. A.} and McFarland, {H. F.}",
year = "2000",
language = "English (US)",
volume = "10",
pages = "817--830",
journal = "Neuroimaging Clinics of North America",
issn = "1052-5149",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - How to participate in a multiple sclerosis clinical trial

AU - Frank, J. A.

AU - McFarland, H. F.

PY - 2000

Y1 - 2000

N2 - MR imaging has made significant and important contributions in the understanding of the natural history of multiple sclerosis. The role of MR imaging and its importance in clinical trials will continue to increase over the next years, not only as a secondary outcome measure in pivotal trials but also as a method of monitoring therapeutic responses in early phase trials. As we move forward in our understanding of the underlying pathophysiology and immunology of MS, correlation with MR imaging measures of disease activity will be essential to translate from the research bench to the patient's bedside, and to use MR imaging more effectively in treatment trials. Neuroimaging groups can provide the required expertise and work together with both clinicians and the pharmaceutical companies in designing MS treatment trials that incorporate clinical and MR imaging outcome measures to determine the effectiveness and long-term benefits to patients of new treatments for MS.

AB - MR imaging has made significant and important contributions in the understanding of the natural history of multiple sclerosis. The role of MR imaging and its importance in clinical trials will continue to increase over the next years, not only as a secondary outcome measure in pivotal trials but also as a method of monitoring therapeutic responses in early phase trials. As we move forward in our understanding of the underlying pathophysiology and immunology of MS, correlation with MR imaging measures of disease activity will be essential to translate from the research bench to the patient's bedside, and to use MR imaging more effectively in treatment trials. Neuroimaging groups can provide the required expertise and work together with both clinicians and the pharmaceutical companies in designing MS treatment trials that incorporate clinical and MR imaging outcome measures to determine the effectiveness and long-term benefits to patients of new treatments for MS.

UR - http://www.scopus.com/inward/record.url?scp=0034449010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034449010&partnerID=8YFLogxK

M3 - Article

C2 - 11359727

AN - SCOPUS:0034449010

VL - 10

SP - 817

EP - 830

JO - Neuroimaging Clinics of North America

JF - Neuroimaging Clinics of North America

SN - 1052-5149

IS - 4

ER -